This database contains 1041 studies, archived under the term: "male"
Click here to filter this large number of results.
Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria
Schmidt, Reinhold,
Baumhackl, Ulf,
Berek, Klaus,
Brücke, Thomas,
Kapeller, Peter,
Lechner, Anita,
Rainer, Michael,
Stögerer, Eva-Maria
We conducted an open, 16-week study on the efficacy of memantine on behavioral disturbances and psychotic symptoms in moderate to moderately severe Alzheimer s disease in daily routine. Fifty-three patients of 20 outpatient centers in Austria were recruited. The Neuropsychiatric Inventory (NPI) was defined as main outcome measure. After 16 weeks the total NPI score […]
Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial
Scheltens, Philip,
Kamphuis, Patrick J. G. H.,
Verhey, Frans R.J.,
Olde Rikkert, Marcel G. M.,
Wurtman, Richard J.,
Wilkinson, David,
Twisk, Jos W.R.,
Kurz, Alexander
Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer’s disease (AD).; Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the […]
Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer’s disease pathophysiological process in routine practice
Sauvée, Mathilde,
DidierLaurent, Guerric,
Latarche, Clotilde,
Escanyé, Marie-Christine,
Olivier, Jean-Luc,
Malaplate-Armand, Catherine
Background: Cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for the diagnosis of Alzheimer’s disease (AD). Since interpretation of CSF profile requires the combination of three parameters, biological data are not always conclusive and isolated elevation of phosphorylated tau (P-tau) or reduction of amyloid-β (Aβ)42 alone can be observed. In these cases, […]
Anhedonia and cognitive impairment in Parkinson’s disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study
Santangelo, G.,
Morgante, L.,
Savica, R.,
Marconi, R.,
Grasso, L.,
Antonini, A.,
De Gaspari, D.,
Ottaviani, D.,
Tiple, D.,
Simoni, L.,
Barone, P.
Objective: To assess the psychometric properties of the Italian version of the Snaith-Hamilton Pleasure Scale (SHAPS) and to study the relationship between anhedonia, depression and cognitive impairment in patients with Parkinson’s disease (PD).; Methods: The SHAPS (14 items) was translated into Italian and pre-tested in a pilot study. Two items evaluating physical anhedonia related to […]
A multidimensional home-based care coordination intervention for elders with memory disorders: the maximizing independence at home (MIND) pilot randomized trial
Samus, Quincy M.,
Johnston, Deirdre,
Black, Betty S.,
Hess, Edward,
Lyman, Christopher,
Vavilikolanu, Amrita,
Pollutra, Jane,
Leoutsakos, Jeannie-Marie,
Gitlin, Laura N,
Rabins, Peter V.,
Lyketsos, Constantine G.
Objectives: To assess whether a dementia care coordination intervention delays time to transition from home and reduces unmet needs in elders with memory disorders.; Design: 18-month randomized controlled trial of 303 community-living elders.; Setting: 28 postal code areas of Baltimore, MD.; Participants: Age 70+ years, with a cognitive disorder, community-living, English-speaking, and having a study […]
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]
Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study
Sakurai, Hirofumi,
Hanyu, Haruo,
Sato, Tomohiko,
Kume, Kazumasa,
Hirao, Kentaro,
Kanetaka, Hidekazu,
Iwamoto, Toshihiko
Aim: It remains unknown whether antiplatelet agents have a preventive effect on cognitive decline in patients with Alzheimer’s disease (AD). We investigated the effects of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, on cognition and regional cerebral blood flow (rCBF) in elderly patients with AD and cerebrovascular disease (CVD).; Methods: A […]